Hirsh, et al., Chem. Abs. No. 123:132873, 1995. |
Roux, et al., Chem. Abs. 118:94100, 1993. |
Faxon, et al., Chem. Abs. No. 101:83760, 1984. |
Beigel et al., Journal of Internal Medicine, “Lovastatin therapy in heterozygous familial hypercholesterolaemic . . . ”, vol. 230, pp. 23-27 (1991). |
Alessandri et al., Current Therapeutic Research, “Effects of Hydroxymethylglutarylcoenzyme a Reductase . . . ”, vol. 53(2), pp. 188-195 (1993). |
Gerique et al., Atherosclerosis, “Effects of Lovastatin and Filicol (A Microporous Cholestyramine) on . . . ”, vol. 115 (Suppl.), p. S105-S105 (1995). |
DiMinno e tal., Arteriosclerosis, “Increased Fibrinogen Binding to Platelets from Patients with Familial Hypercholesterolemia . . . ”, vol. 6, pp. 203-211 (1986). |
Cook, et al., Drugs of the Future, “Platelet glycoprotein IIb/IIIa antagonists”, vol. 19(2), pp. 135-159 (1994). |
Cox, et al., Medicinal Research Reviews, “The Pharmacology of the Integrins”, vol. 14(2), pp. 195-228 (1994). |
Kjekshus, et al., Reducing the Risk of Coronary Events: Evidence from the Scandinavian Simvastatin Survival Study (4S), The American Journal of Cardiology, vol. 76, pp. 64C-68C, 1995. |